CRP and rheumatoid arthritis: The practice of switching between different anti-TNF-α drugs (cycling strategy) has become widespread in the 2000s as a result of limited alternative options.10 In Cohen and colleagues cohort study,11 18 out of 24 RA patients who were switched from infliximab to another anti-TNF-α drug reported significant decrease of disease activity score (DAS) in 28 joints measurements and CRP values.